An update on cardio-oncology

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Over the past decades, there have been great advancements in the survival outcome of patients with cancer. As a consequence, treatment regimens are being extended to patient populations that would not have qualified in the past based on comorbidities and age. Furthermore, the anti-cancer regimens, which have been and are being used, can cause considerable morbidity and even mortality. In fact, new drugs such as tyrosine kinase inhibitors have yielded unanticipated side effects in frequency and severity. The cardiovascular disease spectrum is an important element in all of these. In order to optimize the outcome of cancer patients with cardiovascular diseases existing prior to cancer treatment or developing as a consequence of it, a new discipline called "cardio-oncology" has evolved over the past few years. Herein, we review the latest developments in this field including cardiotoxicities, vascular toxicities, and arrhythmias. This field is taking on more shape as cardiologists, oncologists, and hematologists are forming alliances, programs, and clinics, supported by the development of expert consensus statements on best management approaches and care of the cancer patient with cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)285-295
Number of pages11
JournalTrends in Cardiovascular Medicine
Volume24
Issue number7
DOIs
StatePublished - Oct 1 2014

Fingerprint

Cardiovascular Diseases
Neoplasms
Protein-Tyrosine Kinases
Blood Vessels
Comorbidity
Cardiac Arrhythmias
Consensus
Patient Care
Morbidity
Survival
Mortality
Therapeutics
Pharmaceutical Preparations
Population
Cardiologists
Oncologists
Cardiotoxicity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

An update on cardio-oncology. / Herrmann, Joerg; Lerman, Amir.

In: Trends in Cardiovascular Medicine, Vol. 24, No. 7, 01.10.2014, p. 285-295.

Research output: Contribution to journalArticle

@article{d20b38766f7e40fd9dd1dc4f95c942dd,
title = "An update on cardio-oncology",
abstract = "Over the past decades, there have been great advancements in the survival outcome of patients with cancer. As a consequence, treatment regimens are being extended to patient populations that would not have qualified in the past based on comorbidities and age. Furthermore, the anti-cancer regimens, which have been and are being used, can cause considerable morbidity and even mortality. In fact, new drugs such as tyrosine kinase inhibitors have yielded unanticipated side effects in frequency and severity. The cardiovascular disease spectrum is an important element in all of these. In order to optimize the outcome of cancer patients with cardiovascular diseases existing prior to cancer treatment or developing as a consequence of it, a new discipline called {"}cardio-oncology{"} has evolved over the past few years. Herein, we review the latest developments in this field including cardiotoxicities, vascular toxicities, and arrhythmias. This field is taking on more shape as cardiologists, oncologists, and hematologists are forming alliances, programs, and clinics, supported by the development of expert consensus statements on best management approaches and care of the cancer patient with cardiovascular diseases.",
author = "Joerg Herrmann and Amir Lerman",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.tcm.2014.07.003",
language = "English (US)",
volume = "24",
pages = "285--295",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - An update on cardio-oncology

AU - Herrmann, Joerg

AU - Lerman, Amir

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Over the past decades, there have been great advancements in the survival outcome of patients with cancer. As a consequence, treatment regimens are being extended to patient populations that would not have qualified in the past based on comorbidities and age. Furthermore, the anti-cancer regimens, which have been and are being used, can cause considerable morbidity and even mortality. In fact, new drugs such as tyrosine kinase inhibitors have yielded unanticipated side effects in frequency and severity. The cardiovascular disease spectrum is an important element in all of these. In order to optimize the outcome of cancer patients with cardiovascular diseases existing prior to cancer treatment or developing as a consequence of it, a new discipline called "cardio-oncology" has evolved over the past few years. Herein, we review the latest developments in this field including cardiotoxicities, vascular toxicities, and arrhythmias. This field is taking on more shape as cardiologists, oncologists, and hematologists are forming alliances, programs, and clinics, supported by the development of expert consensus statements on best management approaches and care of the cancer patient with cardiovascular diseases.

AB - Over the past decades, there have been great advancements in the survival outcome of patients with cancer. As a consequence, treatment regimens are being extended to patient populations that would not have qualified in the past based on comorbidities and age. Furthermore, the anti-cancer regimens, which have been and are being used, can cause considerable morbidity and even mortality. In fact, new drugs such as tyrosine kinase inhibitors have yielded unanticipated side effects in frequency and severity. The cardiovascular disease spectrum is an important element in all of these. In order to optimize the outcome of cancer patients with cardiovascular diseases existing prior to cancer treatment or developing as a consequence of it, a new discipline called "cardio-oncology" has evolved over the past few years. Herein, we review the latest developments in this field including cardiotoxicities, vascular toxicities, and arrhythmias. This field is taking on more shape as cardiologists, oncologists, and hematologists are forming alliances, programs, and clinics, supported by the development of expert consensus statements on best management approaches and care of the cancer patient with cardiovascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=84908028393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908028393&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2014.07.003

DO - 10.1016/j.tcm.2014.07.003

M3 - Article

C2 - 25153017

AN - SCOPUS:84908028393

VL - 24

SP - 285

EP - 295

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 7

ER -